Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy.

Bari R, Granzin M, Tsang KS, Roy A, Krueger W, Orentas R, Pfeifer R, Moeker N, Verhoeyen E, Dropulic B, Leung W.

Front Immunol. 2019 Aug 22;10:2001. doi: 10.3389/fimmu.2019.02001. eCollection 2019.

2.

Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model.

Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, Ochsenbauer C, Kappes JC, Krueger W, Worden A, Schneider D, Zhu Z, Orentas R, Dimitrov DS, Goldstein H, Dropulić B.

Sci Transl Med. 2019 Aug 7;11(504). pii: eaav5685. doi: 10.1126/scitranslmed.aav5685.

PMID:
31391322
3.

CD19 CAR T cell product and disease attributes predict leukemia remission durability.

Finney OC, Brakke HM, Rawlings-Rhea S, Hicks R, Doolittle D, Lopez M, Futrell RB, Orentas RJ, Li D, Gardner RA, Jensen MC.

J Clin Invest. 2019 Mar 12;129(5):2123-2132. doi: 10.1172/JCI125423. Print 2019 May 1.

4.

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.

Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, Zhu Z, Croix BS, Delaidelli A, Sekunova A, Bonvini E, Mitra SS, Quezado MM, Majeti R, Monje M, Sorensen PHB, Maris JM, Mackall CL.

Clin Cancer Res. 2019 Apr 15;25(8):2560-2574. doi: 10.1158/1078-0432.CCR-18-0432. Epub 2019 Jan 17.

PMID:
30655315
5.

A Unique Human Immunoglobulin Heavy Chain Variable Domain-Only CD33 CAR for the Treatment of Acute Myeloid Leukemia.

Schneider D, Xiong Y, Hu P, Wu D, Chen W, Ying T, Zhu Z, Dimitrov DS, Dropulic B, Orentas RJ.

Front Oncol. 2018 Nov 22;8:539. doi: 10.3389/fonc.2018.00539. eCollection 2018.

6.

Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.

Zhu F, Shah N, Xu H, Schneider D, Orentas R, Dropulic B, Hari P, Keever-Taylor CA.

Cytotherapy. 2018 Mar;20(3):394-406. doi: 10.1016/j.jcyt.2017.09.005. Epub 2017 Dec 26.

PMID:
29287970
7.

Correction to: Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):327. doi: 10.1007/s00262-017-2102-z.

PMID:
29264697
8.

CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.

Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, Wolters P, Martin S, Delbrook C, Yates B, Shalabi H, Fountaine TJ, Shern JF, Majzner RG, Stroncek DF, Sabatino M, Feng Y, Dimitrov DS, Zhang L, Nguyen S, Qin H, Dropulic B, Lee DW, Mackall CL.

Nat Med. 2018 Jan;24(1):20-28. doi: 10.1038/nm.4441. Epub 2017 Nov 20.

9.

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells.

Moore T, Wagner CR, Scurti GM, Hutchens KA, Godellas C, Clark AL, Kolawole EM, Hellman LM, Singh NK, Huyke FA, Wang SY, Calabrese KM, Embree HD, Orentas R, Shirai K, Dellacecca E, Garrett-Mayer E, Li M, Eby JM, Stiff PJ, Evavold BD, Baker BM, Le Poole IC, Dropulic B, Clark JI, Nishimura MI.

Cancer Immunol Immunother. 2018 Feb;67(2):311-325. doi: 10.1007/s00262-017-2073-0. Epub 2017 Oct 20. Erratum in: Cancer Immunol Immunother. 2017 Dec 20;:.

10.

Paired Expression Analysis of Tumor Cell Surface Antigens.

Orentas RJ, Sindiri S, Duris C, Wen X, He J, Wei JS, Jarzembowski J, Khan J.

Front Oncol. 2017 Aug 21;7:173. doi: 10.3389/fonc.2017.00173. eCollection 2017.

11.

Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.

Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM, Lopomo P, Vigny M, Fry TJ, Orentas RJ, Mackall CL.

Mol Ther. 2017 Sep 6;25(9):2189-2201. doi: 10.1016/j.ymthe.2017.06.008. Epub 2017 Jul 1.

12.

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

Schneider D, Xiong Y, Wu D, Nӧlle V, Schmitz S, Haso W, Kaiser A, Dropulic B, Orentas RJ.

J Immunother Cancer. 2017 May 16;5:42. doi: 10.1186/s40425-017-0246-1. eCollection 2017.

13.

Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas.

Long AH, Highfill SL, Cui Y, Smith JP, Walker AJ, Ramakrishna S, El-Etriby R, Galli S, Tsokos MG, Orentas RJ, Mackall CL.

Cancer Immunol Res. 2016 Oct;4(10):869-880. Epub 2016 Aug 22.

14.

Emerging Immunotherapies for Cancer and Their Potential for Application in Pediatric Oncology.

Orentas RJ, Mackall CL.

Crit Rev Oncog. 2015;20(3-4):315-27. Review.

PMID:
26349422
15.

Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.

Qin H, Cho M, Haso W, Zhang L, Tasian SK, Oo HZ, Negri GL, Lin Y, Zou J, Mallon BS, Maude S, Teachey DT, Barrett DM, Orentas RJ, Daugaard M, Sorensen PH, Grupp SA, Fry TJ.

Blood. 2015 Jul 30;126(5):629-39. doi: 10.1182/blood-2014-11-612903. Epub 2015 Jun 3. Erratum in: Blood. 2016 Sep 8;128(10):1441.

16.

4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.

Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M, Smith JP, Walker AJ, Kohler ME, Venkateshwara VR, Kaplan RN, Patterson GH, Fry TJ, Orentas RJ, Mackall CL.

Nat Med. 2015 Jun;21(6):581-90. doi: 10.1038/nm.3838. Epub 2015 May 4.

17.

Towards a commercial process for the manufacture of genetically modified T cells for therapy.

Kaiser AD, Assenmacher M, Schröder B, Meyer M, Orentas R, Bethke U, Dropulic B.

Cancer Gene Ther. 2015 Mar;22(2):72-8. doi: 10.1038/cgt.2014.78. Epub 2015 Jan 23. Review.

18.

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL.

Lancet. 2015 Feb 7;385(9967):517-528. doi: 10.1016/S0140-6736(14)61403-3. Epub 2014 Oct 13.

PMID:
25319501
19.

Bioinformatic description of immunotherapy targets for pediatric T-cell leukemia and the impact of normal gene sets used for comparison.

Orentas RJ, Nordlund J, He J, Sindiri S, Mackall C, Fry TJ, Khan J.

Front Oncol. 2014 Jun 10;4:134. doi: 10.3389/fonc.2014.00134. eCollection 2014. Review.

20.

A transplantable TH-MYCN transgenic tumor model in C57Bl/6 mice for preclinical immunological studies in neuroblastoma.

Kroesen M, Nierkens S, Ansems M, Wassink M, Orentas RJ, Boon L, den Brok MH, Hoogerbrugge PM, Adema GJ.

Int J Cancer. 2014 Mar 15;134(6):1335-45. doi: 10.1002/ijc.28463. Epub 2013 Sep 14.

21.

Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer.

Zhang H, Maric I, DiPrima MJ, Khan J, Orentas RJ, Kaplan RN, Mackall CL.

Blood. 2013 Aug 15;122(7):1105-13. doi: 10.1182/blood-2012-08-449413. Epub 2013 Jun 11.

22.

Lessons learned from a highly-active CD22-specific chimeric antigen receptor.

Long AH, Haso WM, Orentas RJ.

Oncoimmunology. 2013 Apr 1;2(4):e23621.

23.

Reading the tea leaves of tumor-mediated immunosuppression.

Orentas RJ.

Clin Cancer Res. 2013 Mar 1;19(5):955-7. doi: 10.1158/1078-0432.CCR-12-3792. Epub 2013 Feb 21.

24.

Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.

Orentas RJ, Yang JJ, Wen X, Wei JS, Mackall CL, Khan J.

Front Oncol. 2012 Dec 17;2:194. doi: 10.3389/fonc.2012.00194. eCollection 2012.

25.

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.

Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.

Blood. 2013 Feb 14;121(7):1165-74. doi: 10.1182/blood-2012-06-438002. Epub 2012 Dec 14.

26.

Immunotherapy targets in pediatric cancer.

Orentas RJ, Lee DW, Mackall C.

Front Oncol. 2012 Jan 30;2:3. doi: 10.3389/fonc.2012.00003. eCollection 2012.

27.

The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.

Lee DW, Barrett DM, Mackall C, Orentas R, Grupp SA.

Clin Cancer Res. 2012 May 15;18(10):2780-90. doi: 10.1158/1078-0432.CCR-11-1920. Erratum in: Clin Cancer Res. 2017 Jan 15;23 (2):611.

28.

High-throughput molecular and histopathologic profiling of tumor tissue in a novel transplantable model of murine neuroblastoma: new tools for pediatric drug discovery.

Stauffer JK, Orentas RJ, Lincoln E, Khan T, Salcedo R, Hixon JA, Back TC, Wei JS, Patidar R, Song Y, Hurd L, Tsokos M, Lai EW, Eisenhofer G, Weiss W, Khan J, Wigginton JM.

Cancer Invest. 2012 Jun;30(5):343-63. doi: 10.3109/07357907.2012.664670.

PMID:
22571338
29.

Murine rhabdomyosarcoma is immunogenic and responsive to T-cell-based immunotherapy.

Meadors JL, Cui Y, Chen QR, Song YK, Khan J, Merlino G, Tsokos M, Orentas RJ, Mackall CL.

Pediatr Blood Cancer. 2011 Dec 1;57(6):921-9. doi: 10.1002/pbc.23048. Epub 2011 Apr 1.

PMID:
21462302
30.

Humoral immune response induced by an engineered cell-based neuroblastoma vaccine with or without CD25 blockade.

Zheng J, Orentas R, Yan X, Liu H.

Acta Biochim Biophys Sin (Shanghai). 2011 Feb;43(2):124-32. doi: 10.1093/abbs/gmq123.

PMID:
21266542
31.

Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data.

Kohler ME, Johnson BD, Palen K, Chen QR, Khan J, Orentas RJ.

Cancer Sci. 2010 Nov;101(11):2316-24. doi: 10.1111/j.1349-7006.2010.01694.x.

32.

Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine.

Kohler ME, Hallett WH, Chen QR, Khan J, Johnson BD, Orentas RJ.

Cell Immunol. 2010;265(1):65-73. doi: 10.1016/j.cellimm.2010.07.004. Epub 2010 Jul 17.

33.

CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Norell H, Zhang Y, McCracken J, Martins da Palma T, Lesher A, Liu Y, Roszkowski JJ, Temple A, Callender GG, Clay T, Orentas R, Guevara-Patiño J, Nishimura MI.

Cancer Immunol Immunother. 2010 Jun;59(6):851-62. doi: 10.1007/s00262-009-0810-8. Epub 2010 Jan 6.

34.

Discovery of YB-1 as a new immunological target in neuroblastoma by vaccination in the context of regulatory T cell blockade.

Zheng J, Jing W, Orentas RJ.

Acta Biochim Biophys Sin (Shanghai). 2009 Dec;41(12):980-90.

35.
36.
37.

Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy.

Saad ER, Bresnahan BA, Cohen EP, Lu N, Orentas RJ, Vasudev B, Hariharan S.

Transplantation. 2008 Mar 27;85(6):850-4. doi: 10.1097/TP.0b013e318166cba8.

PMID:
18360267
38.

Recovery of BK virus large T-antigen-specific cellular immune response correlates with resolution of bk virus nephritis.

Prosser SE, Orentas RJ, Jurgens L, Cohen EP, Hariharan S.

Transplantation. 2008 Jan 27;85(2):185-92. doi: 10.1097/TP.0b013e31815fef56.

PMID:
18212622
39.

Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site.

Zhou Q, Johnson BD, Orentas RJ.

Cell Immunol. 2007 Feb;245(2):91-102. Epub 2007 Jun 1.

40.

CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma.

Johnson BD, Jing W, Orentas RJ.

J Immunother. 2007 Feb-Mar;30(2):203-14.

PMID:
17471167
41.

Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen.

Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD, Orentas RJ.

BMC Immunol. 2007 Mar 30;8:4.

42.
43.

Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation.

Yan X, Orentas RJ, Johnson BD.

Cytokine. 2006 Feb 21;33(4):188-98. Epub 2006 Mar 7.

45.

Suppression of anti-cancer immunity by regulatory T cells: back to the future.

Orentas RJ, Kohler ME, Johnson BD.

Semin Cancer Biol. 2006 Apr;16(2):137-49. Epub 2006 Jan 11. Review.

PMID:
16376101
46.

BK virus-specific antibodies and BKV DNA in renal transplant recipients with BKV nephritis.

Hariharan S, Cohen EP, Vasudev B, Orentas R, Viscidi RP, Kakela J, DuChateau B.

Am J Transplant. 2005 Nov;5(11):2719-24.

47.

Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice.

Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ.

J Immunother. 2005 Sep-Oct;28(5):449-60.

PMID:
16113601
48.

Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines.

Gershan JA, Johnson BD, Weber J, Schauer DW, Natalia N, Behnke S, Burns K, Maloney KW, Warwick AB, Orentas RJ.

Genet Vaccines Ther. 2005 Jun 21;3(1):4.

50.

Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related post-transplant lymphoproliferative disorders.

Abed N, Casper JT, Camitta BM, Margolis D, Trost B, Orentas R, Chang CC.

Bone Marrow Transplant. 2004 Feb;33(3):321-7.

PMID:
14688820

Supplemental Content

Loading ...
Support Center